These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

825 related items for PubMed ID: 25202087

  • 21. The Novel HSP90 inhibitor, IPI-493, is highly effective in human gastrostrointestinal stromal tumor xenografts carrying heterogeneous KIT mutations.
    Floris G, Sciot R, Wozniak A, Van Looy T, Wellens J, Faa G, Normant E, Debiec-Rychter M, Schöffski P.
    Clin Cancer Res; 2011 Sep 01; 17(17):5604-14. PubMed ID: 21737509
    [Abstract] [Full Text] [Related]

  • 22. Advanced gastrointestinal stromal tumor in Europe: a review of updated treatment recommendations.
    Blay JY, Reichardt P.
    Expert Rev Anticancer Ther; 2009 Jun 01; 9(6):831-8. PubMed ID: 19496720
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial.
    Kang YK, Ryu MH, Yoo C, Ryoo BY, Kim HJ, Lee JJ, Nam BH, Ramaiya N, Jagannathan J, Demetri GD.
    Lancet Oncol; 2013 Nov 01; 14(12):1175-82. PubMed ID: 24140183
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Clinical significance of pathological complete response in patients with metastatic gastrointestinal stromal tumors after imatinib mesylate treatment--lessons learned.
    Cheng CT, Tsai CY, Yeh CN, Chiang KC, Chen YY, Wang SY, Chen TW, Tseng JH, Jung SM, Chen TC, Yeh TS.
    Anticancer Res; 2014 Nov 01; 34(11):6617-25. PubMed ID: 25368266
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. The role of KIT in the management of patients with gastrointestinal stromal tumors.
    Hornick JL, Fletcher CD.
    Hum Pathol; 2007 May 01; 38(5):679-87. PubMed ID: 17437861
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors (GIST) following failure of at least imatinib and sunitinib.
    Ganjoo KN, Villalobos VM, Kamaya A, Fisher GA, Butrynski JE, Morgan JA, Wagner AJ, D'Adamo D, McMillan A, Demetri GD, George S.
    Ann Oncol; 2014 Jan 01; 25(1):236-40. PubMed ID: 24356634
    [Abstract] [Full Text] [Related]

  • 35. Regorafenib: a guide to its use in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib and sunitinib.
    Lyseng-Williamson KA.
    BioDrugs; 2013 Oct 01; 27(5):525-31. PubMed ID: 23975637
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Managing progressive disease in patients with GIST: factors to consider besides acquired secondary tyrosine kinase inhibitor resistance.
    Patel S.
    Cancer Treat Rev; 2012 Aug 01; 38(5):467-72. PubMed ID: 22035971
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure.
    Demetri GD, Heinrich MC, Fletcher JA, Fletcher CD, Van den Abbeele AD, Corless CL, Antonescu CR, George S, Morgan JA, Chen MH, Bello CL, Huang X, Cohen DP, Baum CM, Maki RG.
    Clin Cancer Res; 2009 Sep 15; 15(18):5902-9. PubMed ID: 19737946
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 42.